Axomadol

Axomadol
Clinical data
ATC code	None;
Legal status
Legal status	US: ?;
Identifiers
	IUPAC name (1R,3R,6R)-6-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-1,3-cyclohexanediol;
CAS Number	187219-95-0 ; 187219-99-4;
PubChem CID	10221318;
ChemSpider	8396810;
UNII	B77S5W28H9;
CompTox Dashboard (EPA)	DTXSID10171992 ;
Chemical and physical data
Formula	C16H25NO3
Molar mass	279.380 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O[C@]2(c1cc(OC)ccc1)C[C@H](O)CC[C@@H]2CN(C)C;
	InChI InChI=1S/C16H25NO3/c1-17(2)11-13-7-8-14(18)10-16(13,19)12-5-4-6-15(9-12)20-3/h4-6,9,13-14,18-19H,7-8,10-11H2,1-3H3/t13-,14-,16+/m1/s1; Key:LQJLLAOISDVBJM-FMKPAKJESA-N;

Axomadol (INN, USAN) (code name EN3324) is a synthetic, centrally-acting opioid analgesic related to tramadol which was under investigation by Endo Pharmaceuticals in collaboration with Grünenthal GmbH for the treatment of chronic, moderate to severe lower back pain and arthrosis.^[1]^[2] Development was halted after phase II clinical trials as it did not meet the pre-determined clinical endpoints.^[3]